Skip to main content
Caplight Logo









WindMIL Therapeutics

WindMIL Therapeutics

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://windmiltx.com/

Last Round

Series B

Jun 18, 2018

Total Funding Raised

$43.5M

Company Overview

WindMIL Therapeutics is a biotechnology company that develops autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapymarrow-infiltrating lymphocytesMILsCAR-MILsimmunotherapyautologous cell therapycancer immunotherapynext-gen CAR-Thematologic malignanciessolid tumor treatmentbone marrow immunologyclinical-stage biotechliving drugscdmo

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

WindMIL Therapeutics Comparables

Compare WindMIL Therapeutics with similar companies based on industry and business-model similarity.

WindMIL Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Triumvira Immunologics
81%
Marker Therapeutics Inc
77%
Rapa Therapeutics
76%

WindMIL Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 18, 2018
Series AMar 24, 2016

WindMIL Therapeutics Investors

Notable investors and investment history

WindMIL Therapeutics investors
InvestorRounds
FoxkiserSeries B, Series A
Domain AssociatesSeries B, Series A
Kintegral Asset ManagementSeries B
QimingSeries B
Forward Equity PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2018

    $33M round led by Qiming

  • Mar 24, 2016

    $11M round led by Domain Associates.

WindMIL Therapeutics Filings

Explore SEC and related filing metadata, where available.

WindMIL Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about WindMIL Therapeutics's valuation, stock price, and market status.

Is WindMIL Therapeutics a public or private company?

WindMIL Therapeutics is a private company.

What is the current stock price of WindMIL Therapeutics?

WindMIL Therapeutics is a private company with no public stock price. Caplight tracks WindMIL Therapeutics's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is WindMIL Therapeutics worth (valuation)?

Valuation information for WindMIL Therapeutics is not publicly available.

Can I buy WindMIL Therapeutics stock?

WindMIL Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was WindMIL Therapeutics's last funding round?

WindMIL Therapeutics's most recent funding round was Series B on June 18, 2018.

Who are the main investors in WindMIL Therapeutics?

Key investors in WindMIL Therapeutics include Domain Associates, Qiming.

Will WindMIL Therapeutics IPO soon?

No public IPO plans have been announced for WindMIL Therapeutics.

How can I track WindMIL Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor WindMIL Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range9
Year Founded2016
Last FundingJun 18, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?